SCHEMBL5322339

SCHEMBL5322339

O=C(c1ccc([N+](=O)[O-])o1)N1CCOCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 1.00
KMT2A Q03164 4/20 0.62
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CHRNA4 P43681 1/20 0.59
RAB9A P51151 5/20 0.57
NPC1 O15118 2/20 0.57
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
SLC2A1 P11166 4/20 0.55
POLB P06746 2/20 0.55
PKM P14618 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MITF O75030 2/20 0.54
CSF1R P07333 1/20 0.54
HSP90AA1 P07900 1/20 0.54
DDIT3 P35638 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427074 0.84 ALDH1A1 (0.72) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427542 0.82 ALDH1A1 (0.69) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349311 0.81 POLB (0.76) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6427605 0.80 ALDH1A1 (0.66) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349326 0.80 ALDH1A1 (0.66) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6428068 0.79 CA12 (0.72) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349313 0.78 ALDH1A1 (0.63) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL31349296 0.78 POLB (0.66) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL6429048 0.78 ALDH1A1 (0.63) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL12443384 0.77 ALDH1A1 (0.62) ALDH1A1KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562019-B2 Substituted pyridazines as EGFR and/or KRAS inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2017-02-07 US disclosed
US-9562019-B2 Substituted pyridazines as EGFR and/or KRAS inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2017-02-07 US disclosed
EP-2518063-B1 Pyridazinones and furan-containing compounds SLOAN-KETTERING INST FOR CANCER RES (US) 2017-02-01 EP disclosed
US-20130131062-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DJABALLAH HAKIM (US) 2013-05-23 US disclosed
US-20100210649-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-08-19 US disclosed
WO-2007113644-A2 NEW HDAC INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-10-11 WO disclosed
WO-2007113644-A2 NEW HDAC INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131062-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DPYD, PDXK, TYMP ALDH1A1 761/4885KMT2A 3872/4885CA12 4795/4885
US-20100210649-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DPYD, PDXK, TYMP ALDH1A1 761/4885KMT2A 3872/4885CA12 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.